A large number of studies used TNBC cell lines, each of which has a characteristic feature regarding the expression pattern of AR or ER-β, and examined the effect of suspected agonists or antagonists, including agents used in endocrine therapy for prostatic or breast cancer. Here, ESR2 is linked to breast carcinoma.